Breast Cancer, Cancer, Head and Neck Cancer, Lymphoma, Melanoma, Triple-Negative Breast Cancer
Conditions
Keywords
Transdermal accessible tumours
Brief summary
The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune responses, as monotherapy or in combination with ipilimumab or pembrolizumab.
Detailed description
In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in patients with transdermally accessible tumours; the safety, PK and efficacy of different dosing regimens of LTX-315 will be assessed. Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and the number of lesions available. Arm A: Single lesion/sequential lesion treatment arm (LTX-315 monotherapy) (Completed) Arm B: Concurrent multiple lesion treatment arm with all tumour types (LTX-315 monotherapy) Arm C: LTX-315 combination with ipilimumab in patients with melanoma Arm D: LTX-315 combination with pembrolizumab in patients with TNBC All patients will have at least one lesion available for injection. Treatment schedule: Arm A: Injection of LTX-315 3 days week 1, 1 day in week 2, 3, 4, 5 and 6. Every 2 weeks starting with week 8. Arm B (all tumours): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16). Arm C (melanoma): Injection of lTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in combination with ipilimumab given in week 1 and every 3 weeks 4 cycles. Arm D (TNBC): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in combination with pembrolizumab given in week 1 and every 3 weeks up to 2 years. Patients will be enrolled into a dose cohort in order of study entry. Staring with the lowest dose. A minimum of 3 patients will be enrolled into each cohort. Dose escalation determined by the Safety Review Committee and the Sponsor. The the optimal regimen will be based on the results of the Dose Escalation from the following information: 1. Safety parameters including blood samples and cardiovascular effects 2. Immunohistology and ultrasound confirmation of necrosis and tumour infiltrating lymphocytes 3. Systemic inflammatory response 4. Evidence of clinical responses Cohorts may be utilized to: 1. Evaluate different doses of LTX-315 2. Explore potential modifications to the dosing schedule 3. Evaluate the potential to include appropriate combination therapies with LTX-315 4. Gain further information on clinical efficacy
Interventions
DRUGLTX-315 consecutive lesions
Dose escalation: Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)
DRUGLTX-315
Dose escalation: Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection
DRUGLTX-315 + ipilimumab
Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
Sponsors
Theradex
ICON plc
Lytix Biopharma AS
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Arm A: (Recruitment completed) Arm B: * Unresectable metastatic disease (any tumor type) and conventional anti-tumor treatment is not appropriate. * Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for injection between 1-3 cm longest diameter and one bystander lesion (non-injected). Arm C: * Have unresectable/metastatic diagnosis of malignant melanoma (histologically confirmed). * Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for injection and biopsy which is between 1 and 3 cm in longest diameter. * Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of combination (any combination) as 1st or 2nd line metastatic treatment). Arm D: * Have unresectable/metastatic diagnosis of triple negative breast cancer (histologically confirmed). * Have at least one available lesion (cutaneous, sub-cutaneous or lymph node) for injection and biopsy with a minimum longest diameter of 1 cm. * Have received between one and 4 prior systemic treatments for metastatic triple negative breast cancer. All arms: * Be willing to undergo repeat tumour biopsy and/or tumour resection procedures. * Have an ECOG Performance status (PS): 0 - 1. * Meet the following laboratory requirements: 1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L 2. Absolute lymphocyte count ≥ 0.8 x 109/L 3. Platelet count ≥ 75 x 109/L 4. Haemoglobin ≥ 9.0 g/dL 5. aPTT/PT within the institution's normal range 6. Total bilirubin level ≤ 1.5 x ULN 7. ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis present) 8. Creatinine ≤ 1.5 x ULN 9. Albumin ≥ 30 g/L
Exclusion criteria
Arm A: (Completed) Arm B: * Have a history of systemic auto-immune disease requiring anti-inflammatory or immunosuppressive therapy within the last 3 months. Patients with history of autoimmune thyroiditis are eligible provided the patient requires only thyroid hormone replacement therapy and disease has been stable for ≥ 1 year. Arm C: * Have had prior therapy with ipilimumab or any other anti-CTLA-4 monoclonal antibody. * Have had BRAF/MEK inhibitors administered within 2 weeks prior to the study drug administration. * Have active systemic autoimmune disease; have had prior pneumonitis; have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; have a history of severe immune-related adverse reaction from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity requiring corticosteroid treatment (\> 10 mg/day prednisone or equivalent) for greater than 12 weeks. Arm D: * Have had prior therapy with an anti-PD-1 or anti-PD-L1 monoclonal antibody. * Have received cancer immunotherapy within 2 weeks prior to study drug administration or have not recovered from adverse events (to ≤ CTCAE grade 1) due to such agents. * Have active systemic autoimmune disease; have had prior pneumonitis; have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; and have a history of severe immune-related adverse reactions from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity requiring corticosteroid treatment (\> 10 mg/day prednisone or equivalent) for greater than 12 weeks. All arms: * Have received external radiotherapy or cytotoxic chemotherapy within 4 weeks prior to study drug administration, or have not recovered from adverse events (≤ CTCAE grade 1) due to agents administered more than 4 weeks earlier. Palliative radiotherapy to non-target lesions within 4 weeks prior to study drug administration is allowed. * Are currently taking any agent with a known effect on the immune system. Patients are allowed to be on a stable dose of corticosteroids (up to 10 mg daily prednisolone or equivalent) for at least 2 weeks prior to study drug administration (please see Appendix IV for prohibited medications). * Have any other serious illness or medical condition such as, but not limited to: 1. Uncontrolled infection or infection requiring antibiotics 2. Uncontrolled cardiac failure: Classification III or IV (New York Heart Association) 3. Uncontrolled systemic and gastro-intestinal inflammatory conditions 4. Bone marrow dysplasia * Have a known history of positive tests for HIV/AIDS, or have active hepatitis B or C (based on serology). * Are expected to need any other anti-cancer therapy or immunotherapy to be initiated during the study period. 15\. Have clinically active or unstable CNS metastases as assessed by the treating physician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicity | 21 days | Dose limiting toxicities (DLT) and the overall safety profile (adverse events (AE), laboratory assessments, physical findings and symptomatic assessment) of LTX-315 as monotherapy and in combination with ipilimumab or pembrolizumab. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete response (irCR) and partial response (irPR) | Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed | Number of patients by irRC |
| Overall response rate (OR) | Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed | (irRC criteria) |
| Anti tumour activity in injected tumour | Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed | Number of patients with regression of injected tumour assessed by ultrasound and/or CT/MRI. |
| Progression free survival (PFS) | Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed | irRC criteria |
| Disease control rate (CR + PR + SD) | Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed | irRC criteria |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic (PK) profile of LTX-315 | Pre and 1 hour post dosing Day 2 Week 1 | Measurement of plasma concentrations of LTX-315 pre- and 1 hour post-dosing day 2 in week 1. |
Countries
Belgium, France, Italy, Norway, United Kingdom
Outcome results
None listed